Ontologías de dominio y herramientas IIIF: una aproximación al fondo de manuscritos poéticos de la Real Biblioteca

Domain ontologies, specifically RDA and POSTDATA, together with IIIF, are the technologies used for a bibliographical and literary approach to the Royal Library's collection of poetic manuscripts and their online publication in the context of a digital library. Special emphasis is given to aspects related to the study of provenance, such as copy marks or part-whole relationships for the reconstruction of a structurally complex collection, and, outside the bibliographic domain, poetic analysis is also considered.Las ontologías de dominio, en concreto RDA y POSTDATA, junto con IIIF, son las tecnologías utilizadas para una aproximación bibliográfica y literaria a la colección de manuscritos poéticos de la Real Biblioteca y su publicación online en el contexto de una biblioteca digital. Se da especial énfasis a los aspectos relacionados con el estudio de la procedencia, tales como las marcas de ejemplar o las relaciones parte-todo para la reconstrucción de un fondo estructuralmente complejo, y, al margen del dominio bibliográfica, se considera también el análisis poétic

una aproximación al fondo de manuscritos poéticos de la Real Biblioteca

Las ontologías de dominio, en concreto RDA y POSTDATA, junto con IIIF, son las tecnologías utilizadas para una aproximación bibliográfica y literaria a la colección de manuscritos poéticos de la Real Biblioteca y su publicación online en el contexto de una biblioteca digital. Se da especial énfasis a los aspectos relacionados con el estudio de la procedencia, tales como las marcas de ejemplar o las relaciones parte-todo para la reconstrucción de un fondo estructuralmente complejo, y, al margen del dominio bibliográfica, se considera también el análisis poético.Domain ontologies, specifically RDA and POSTDATA, together with IIIF, are the technologies used for a bibliographical and literary approach to the Royal Library's collection of poetic manuscripts and their online publication in the context of a digital library. Special emphasis is given to aspects related to the study of provenance, such as copy marks or part-whole relationships for the reconstruction of a structurally complex collection, and, outside the bibliographic domain, poetic analysis is also considere

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

ISB(u)N. International Standard Book (u)nreal Number. Índice gris de publicaciones de arte contemporáneo

  ISB(u)N plantea la autoedición de índices de referencias bibliográficas de publicaciones de arte contemporáneo no registradas según el Sistema Internacional Estandarizado. Basado en la idea de “libro de libros”, la versión en papel (Volumen 0, inicio de la colección) da auspicio, bajo un único número de registro, a un listado/fichas de material documental generado en el campo de la creación artística actual, haciendo factible su localización y visibilidad a través de los canales de distribución editorial. La versión digital se presenta como núcleo/rizoma de una propuesta en crecimiento, dando la posibilidad de acceso a los recursos de la investigación. Alejado de la idea de biblioteca total, el trabajo quiere poner de manifiesto la importancia de la figura del autor/editor y la necesidad de atención sobre un foco editorial relegado al olvido, como ha sido y es el de la producción artística.    ISB(u)N. International Standard Book (u)nreal Number. Grey index of contemporary art publications Abstract ISB(u)N proposes the self-publishing of indexes of bibliographical references of contemporary art publications that have not been registered according to the International Organization for Standardization. Based on the idea of “a book of books”, the print version (Volumen 0, the beginning of the collection) harnesses, under a single registry number, a list of index cards of documentary material generated in the field of contemporary art creation, making feasible its localisation and visibility through the channels of publishing distribution. The digital version is presented as a rhizome-kernel of a growing project, providing access to the resources used during the research. Far removed from the idea of a total library, the project wants to shed light on the importance of the figure of the author-publisher and the need to acknowledge a publishing focus which has been abandoned to oblivion, as has been, and still is, the case of art production

ISB(u)N. International Standard Book (u)nreal Number. Índice gris de publicaciones de arte contemporáneo

ISB(u)N proposes the self-publishing of indexes of bibliographical references of contemporary art publications that have not been registered according to the International Organization for Standardization. Based on the idea of “a book of books”, the print version (Volumen 0, the beginning of the collection) harnesses, under a single registry number, a list of index cards of documentary material generated in the field of contemporary art creation, making feasible its localisation and visibility through the channels of publishing distribution. The digital version is presented as a rhizome-kernel of a growing project, providing access to the resources used during the research. Far removed from the idea of a total library, the project wants to shed light on the importance of the figure of the author-publisher and the need to acknowledge a publishing focus which has been abandoned to oblivion, as has been, and still is, the case of art productionISB(u)N plantea la autoedición de índices de referencias bibliográficas de publicaciones de arte contemporáneo no registradas según el Sistema Internacional Estandarizado. Basado en la idea de “libro de libros”, la versión en papel (Volumen 0, inicio de la colección) da auspicio, bajo un único número de registro, a un listado/fichas de material documental generado en el campo de la creación artística actual, haciendo factible su localización y visibilidad a través de los canales de distribución editorial. La versión digital se presenta como núcleo/rizoma de una propuesta en cre-cimiento, dando la posibilidad de acceso a los recursos de la investigación. Alejado de la idea de biblioteca total, el trabajo quiere poner de manifiesto la importancia de la fi-gura del autor/editor y la necesidad de atención sobre un foco editorial relegado al olvido, como ha sido y es el de la producción artístic

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society